Skip to content
Markets News
Stocks1 min read

IDEX Beats the S&P 500 Year to Date, but Recent Weakness Shows

Makkler Newsroom
September 24, 2026 · Based on reporting by Barchart

IDEX shares lagged the index over three months, despite stronger year-to-date and one-year gains as industrial orders climbed.

IDEX Corporation shares outperformed the S&P 500 over the year to Sept. 22, 2026, but fell behind the index over the prior three months. IDEX, traded on the New York Stock Exchange as IEX, gained 25.1% year to date and 38.2% over 52 weeks.

Over three months, IDEX shares lost 1.1%, while the S&P 500 rose 3.5%, according to Barchart’s comparison. The results show how the measurement window changes the picture: IDEX’s longer-term gains are strong, but its recent momentum has weakened.

The stock was also below its 50-day moving average, a measure of its average price over roughly 10 weeks, from early September. It remained above its 200-day average, which tracks a longer stretch of trading and can help show the broader trend.

Business results offer one reason investors have backed the shares this year. IDEX reported second-quarter sales of $920.6 million, up 6% from a year earlier, and adjusted earnings of $2.32 per share, a 12% increase.

Orders provided another positive signal. The company said total orders rose 28% organically, excluding acquisitions and currency effects, while orders in its Health & Science Technologies segment climbed 47%.

IDEX linked demand in that segment to data centers, semiconductors, and space and defense markets. The company raised its 2026 adjusted earnings outlook to $8.70 to $8.85 per share after the quarter.

The next test is whether those orders turn into sales and earnings while the share price regains short-term momentum. IDEX is scheduled to report its next quarterly results in November, according to the company’s investor calendar.

Topics
IEXS&P 500
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.